Acorda Therapeutics (ACOR) Misses Q2 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Oil settles up over $2 as Iran war stalemate stokes supply concerns
- L3Harris CEO steps down amid conduct review, shares drop
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
Acorda Provides Financial and Pipeline Update for Second Quarter 2016
July 28, 2016 6:00 AM EDTAMPYRA® (dalfampridine) 2Q 2016 Net Revenue of $122.1 Million; 16% Increase over 2Q 2015 Net Revenue of $105.5 Million Company Reiterates AMPYRA 2016 Net Sales Guidance and Provides Updates on 2016 R&D and SG&A Guidance Upcoming Clinical Trial Data on Dalfampridine in Post-Stroke Walking Difficulties (2H 2016) and CVT-301 for OFF Periods in Parkinsons Disease (1Q 2017)
ARDSLEY, N.Y.--(BUSINESS WIRE)-- Acorda Therapeutics, Inc.... More
